BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

[1]  N. Yao,et al.  Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer. , 2023, European journal of medicinal chemistry.

[2]  J. Black,et al.  Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins , 2023, The Journal of biological chemistry.

[3]  A. Tolcher,et al.  Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. , 2022, Clinical Cancer Research.

[4]  S. Sleijfer,et al.  First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. , 2022, European journal of cancer.

[5]  A. Strasser,et al.  The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs , 2021, Nature Reviews Cancer.

[6]  A. Tolcher,et al.  A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation , 2021, Clinical Cancer Research.

[7]  G. Fabbri,et al.  Abstract 1107: Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition , 2021, Experimental and Molecular Therapeutics.

[8]  M. Reddy,et al.  Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer , 2021, Molecules.

[9]  R. Rosell,et al.  Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer , 2020, Molecular oncology.

[10]  M. Roth,et al.  Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs , 2020, Cancer Research.

[11]  D. Galetta,et al.  Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases , 2020, Cancers.

[12]  Naga Rajiv Lakkaniga,et al.  Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. , 2020, European journal of medicinal chemistry.

[13]  A. Villunger,et al.  Uncovering the PIDDosome and caspase-2 as regulators of organogenesis and cellular differentiation , 2020, Cell Death & Differentiation.

[14]  H. Briem,et al.  Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. , 2020, Journal of medicinal chemistry.

[15]  J. Sandow,et al.  Phosphorylation by Aurora B kinase regulates caspase-2 activity and function , 2020, bioRxiv.

[16]  Marc Hafner,et al.  A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines , 2019, Cell systems.

[17]  R. Rosell,et al.  AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy , 2019, Nature Communications.

[18]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[19]  D. Root,et al.  Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. , 2018, Cancer discovery.

[20]  Huimin Bian,et al.  Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene. , 2018, Cancer discovery.

[21]  Sourav Bandyopadhyay,et al.  Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer , 2018, Nature Medicine.

[22]  Sharad Kumar,et al.  p53 accumulation following cytokinesis failure in the absence of caspase-2 , 2018, Cell Death & Differentiation.

[23]  Benjamin Haibe-Kains,et al.  Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer , 2018, Proceedings of the National Academy of Sciences.

[24]  A. Villunger,et al.  The resurrection of the PIDDosome – emerging roles in the DNA-damage response and centrosome surveillance , 2017, Journal of Cell Science.

[25]  H. Ditzel,et al.  Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.

[26]  G. Zaman,et al.  TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers , 2017, Molecular Cancer Therapeutics.

[27]  S. Barry,et al.  Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles , 2017, Molecular Cancer Therapeutics.

[28]  T. Mak,et al.  Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer , 2017, Proceedings of the National Academy of Sciences.

[29]  F. López-Ríos,et al.  Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. , 2017, Clinical chemistry.

[30]  Junnian Zheng,et al.  Aurora kinases: novel therapy targets in cancers , 2017, Oncotarget.

[31]  S. Geley,et al.  The PIDDosome activates p53 in response to supernumerary centrosomes , 2017, Genes & development.

[32]  E. Schröck,et al.  Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny. , 2016, Carcinogenesis.

[33]  M. Scheulen,et al.  A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[34]  S. Barry,et al.  Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo , 2016, Science Translational Medicine.

[35]  P. Lienau,et al.  Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity , 2016, Molecular Cancer Therapeutics.

[36]  M. Narita,et al.  Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition , 2015, Molecular biology of the cell.

[37]  J. Nilsson,et al.  Regulation of mitotic progression by the spindle assembly checkpoint , 2015, Molecular & cellular oncology.

[38]  Y. Yatabe,et al.  CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. , 2014, Lung cancer.

[39]  C. Sotiriou,et al.  TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers , 2014, Molecular oncology.

[40]  C. Streuli,et al.  Phosphorylation of the Proapoptotic BH3-Only Protein Bid Primes Mitochondria for Apoptosis during Mitotic Arrest , 2014, Cell reports.

[41]  L. Galluzzi,et al.  Characterization of novel MPS1 inhibitors with preclinical anticancer activity , 2013, Cell Death and Differentiation.

[42]  S. Gaubatz,et al.  A role for p38 in transcriptional elongation of p21CIP1 in response to Aurora B inhibition , 2013, Cell cycle.

[43]  G. Shapiro,et al.  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors , 2013, Investigational New Drugs.

[44]  R. Splittgerber,et al.  Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence , 2012, EMBO molecular medicine.

[45]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[46]  William C Hahn,et al.  Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. , 2011, Cancer discovery.

[47]  D. Green,et al.  Caspase-2: the orphan caspase , 2011, Cell Death and Differentiation.

[48]  Alan Mackay,et al.  Functional viability profiles of breast cancer. , 2011, Cancer discovery.

[49]  T. Jacks,et al.  Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. , 2011, Molecular cell.

[50]  J. Schellens,et al.  Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  J. Mate,et al.  Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations , 2011, Clinical Cancer Research.

[52]  T. Dansen,et al.  Release of Mps1 from kinetochores is crucial for timely anaphase onset , 2010, The Journal of cell biology.

[53]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[54]  Mong-Hong Lee,et al.  Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer , 2010, Molecular Cancer.

[55]  G. Schwartz,et al.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. , 2009, Molecular biology of the cell.

[56]  D. Green,et al.  Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3 , 2008, Cell.

[57]  R. Medema,et al.  Mps1 Phosphorylates Borealin to Control Aurora B Activity and Chromosome Alignment , 2008, Cell.

[58]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[59]  A. Gross,et al.  Bid Plays a Role in the DNA Damage Response , 2007, Cell.

[60]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[61]  E. Salmon,et al.  The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.

[62]  D. Green,et al.  Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death. , 2006, Molecular biology of the cell.

[63]  M. Kastan.  Cell biology: A BID for the pathway , 2005, Nature.

[64]  Y. Lerenthal,et al.  Proapoptotic BID Is an ATM Effector in the DNA-Damage Response , 2005, Cell.

[65]  Stephen S. Taylor,et al.  Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20 , 2005, Journal of Cell Science.

[66]  M. Meyerson,et al.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. , 2005, Cancer research.

[67]  J. Tschopp,et al.  The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress , 2004, Science.

[68]  L. Owen-Schaub,et al.  Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers* , 2003, Journal of Biological Chemistry.

[69]  A. Rebbaa,et al.  Caspase inhibition switches doxorubicin-induced apoptosis to senescence , 2003, Oncogene.

[70]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[71]  S. Srinivasula,et al.  Caspase-2 Induces Apoptosis by Releasing Proapoptotic Proteins from Mitochondria* , 2002, The Journal of Biological Chemistry.

[72]  S. Korsmeyer,et al.  Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. , 2000, Science.

[73]  C. Milliman,et al.  BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.

[74]  C. Penny,et al.  Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. , 2021, Mutation research.